Effects of novel therapies on heart failure patients investigate the efficacy and safety of emerging treatments or therapies for heart failure management
Ali, Muhammad Younas Ullah, Obaid Sikandar, Irsa Noor, Muhammad Amin Ahmad, Faizan Yousaf, Aima Jan, Ayiz Rukh, Mah Khan, Adeel
Ali, Muhammad Younas
Ullah, Obaid
Sikandar, Irsa
Noor, Muhammad Amin
Ahmad, Faizan
Yousaf, Aima
Jan, Ayiz
Rukh, Mah
Khan, Adeel
Affiliation
Gajju Khan Medical College, Swabi, Pakistan; South Tyneside and Sunderland NHS Foundation Trust; Lady Reading Hospital, Peshawar, Pakistan; Naseer Teaching Hospital, Peshawar, Pakistan; George Eliot Hospital, Nuneaton; Khyber Teaching Hospital, Peshawar, Pakistan
Other Contributors
Publication date
2024-04-16
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Background: Heart failure (HF) is a serious worldwide health issue that is defined by the heart's incapacity to adequately pump blood to meet the body's needs
Objective: The research main objective was to examine the safety and effectiveness of novel medications or treatments for the management of HF.
Methodology: The purpose of this prospective cohort study was to assess the safety and effectiveness of new heart failure treatments at MTI Lady Reading Hospital Peshawar, Pakistan. A total of 320 adult patients with heart failure (HFpEF or HFrEF) were enrolled between 1st April 2020 and 26th March 2023. Comprehensive data was collected using structured data collecting forms, and treatment outcomes were assessed using follow-up examinations conducted at 3, 6, and 12 months. Subgroup studies based on HF subtype were planned, and descriptive and inferential statistical analyses were used to compare results between innovative and traditional therapy.
Results: The groups' baseline characteristics were comparable. The mean ejection fraction increased by +8.4% (±3.6) in the Novel Therapy group (NTG) and +5.9% (±2.8) in the Standard Therapy group (STG) (p < 0.001). Furthermore, improvement in NYHA functional class was observed in a larger proportion of patients in the NTG (76.2% vs. 62.5%, p = 0.013). According to the Kansas City Cardiomyopathy Questionnaire, the group receiving novel therapy had a considerably higher quality of life (45.7 ± 6.3) than the group receiving standard therapy (39.5 ± 7.1) (p < 0.001). The group receiving Novel Therapy saw fewer hospitalizations (15.6%) for worsening heart failure than the group receiving Standard Therapy (23.8%) (p = 0.049). There was no discernible difference in mortality rates across the groups (6.3% vs. 9.4%, p = 0.214).
Conclusion: Comparing novel therapy to established treatments, there were notable improvements in heart function, symptom management, and quality of life. These results highlight the necessity for ongoing research and individualized treatment plans, and they promote the inclusion of novel therapies in HF care protocols.
Citation
Ali MY, Ullah O, Sikandar I, Noor MA, Ahmad F, Yousaf A, Jan A, Rukh M, Khan A. EFFECTS OF NOVEL THERAPIES ON HEART FAILURE PATIENTS INVESTIGATE THE EFFICACY AND SAFETY OF EMERGING TREATMENTS OR THERAPIES FOR HEART FAILURE MANAGEMENT. J Popul Ther Clin Pharmacol. 2024;31(4):1115-1124. doi: 10.53555/jptcp.v31i4.5668.
Type
Article